Mutant IDH1-IN-4 is primarily used in cancer research, specifically targeting cancers associated with mutations in the isocitrate dehydrogenase 1 (IDH1) gene. It acts as an inhibitor, blocking the activity of mutant IDH1 enzymes, which are known to produce an oncometabolite called 2-hydroxyglutarate (2-HG). This metabolite drives tumor growth in certain cancers, such as gliomas and acute myeloid leukemia (AML). By inhibiting mutant IDH1, this compound helps reduce 2-HG levels, potentially slowing or halting cancer progression. It is a valuable tool in preclinical studies for understanding the role of IDH1 mutations in cancer biology and for developing targeted therapies. Additionally, it aids in evaluating the efficacy of IDH1 inhibitors in experimental models, contributing to advancements in precision medicine for cancer treatment.